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CCN, CCTn, CCTt:

:   normal liver tissues (N) and the nontumor (Tn) and tumor tissues (Tt) of tumor‐bearing livers of F2 males obtained by crossing control sires and control dams

AAN, AATn, AATt:

:   normal liver tissues (N) and the nontumor (Tn) and tumor tissues (Tt) of tumor‐bearing livers of F2 males obtained by gestationally arsenite‐exposed F1 sires and gestationally arsenite‐exposed F1 dams

1. INTRODUCTION {#cas14104-sec-0001}
===============

Multigenerational adverse effects from environmental factors are one of the important concerns for health.[1](#cas14104-bib-0001){ref-type="ref"} In pregnant females (designated as the filial (F)0 generation), chemical exposure interacts not only with their offspring (F1 generation) but also the germ cells, the origin of their grandchildren (F2 generation), developing within the F1 animal.[2](#cas14104-bib-0002){ref-type="ref"} Exposure of pregnant F0 mice to various environmental factors has been reported to cause harmful health effects, such as metabolic disorders and cancers, in the F2 as well as the F1 generations.[3](#cas14104-bib-0003){ref-type="ref"}, [4](#cas14104-bib-0004){ref-type="ref"}, [5](#cas14104-bib-0005){ref-type="ref"}

Epidemiological studies have reported an increased risk of carcinogenesis in adulthood by gestational arsenic exposure.[6](#cas14104-bib-0006){ref-type="ref"}, [7](#cas14104-bib-0007){ref-type="ref"}, [8](#cas14104-bib-0008){ref-type="ref"} Previous studies have reported that gestational arsenite exposure increased hepatic tumor incidence in F1 males in C3H mice,[9](#cas14104-bib-0009){ref-type="ref"}, [10](#cas14104-bib-0010){ref-type="ref"} whose males tend to develop spontaneous hepatic tumors.[11](#cas14104-bib-0011){ref-type="ref"} In the same experimental model,[9](#cas14104-bib-0009){ref-type="ref"}, [10](#cas14104-bib-0010){ref-type="ref"} we found that hepatic tumor incidence was increased even in the F2 males born to the F1 males gestationally exposed to arsenite compared with F2 males of control group, irrespective of exposure of F1 females.[12](#cas14104-bib-0012){ref-type="ref"} However, the mechanisms of hepatic tumor increase in the F2 by gestational arsenic exposure have not yet been clarified.

Epigenetic changes are inheritable and are suspected to be associated with multigenerational and transgenerational effects.[13](#cas14104-bib-0013){ref-type="ref"} Epigenetics is a regulation system of gene expression without changing DNA sequences. DNA methylation, histone modifications, and noncoding RNAs are known as major epigenetic modifications.[14](#cas14104-bib-0014){ref-type="ref"} The most abundant epigenetic mark of DNA is methylation of carbon 5 of cytosines, which creates 5‐methylcytosine (5mC). In addition, 5‐hydroxymethylcytosine (5hmC), an intermediate metabolite of 5mC in the active demethylation process, is another epigenetically modified base.[15](#cas14104-bib-0015){ref-type="ref"} Those methylation changes are related to adverse health effects including cancer.[16](#cas14104-bib-0016){ref-type="ref"}, [17](#cas14104-bib-0017){ref-type="ref"} Total levels of 5mC and 5hmC are known to be reduced in cancer tissues, and can compromise genomic integrity and lead to tumor growth.[18](#cas14104-bib-0018){ref-type="ref"}, [19](#cas14104-bib-0019){ref-type="ref"} In tumor tissues, site‐specific hypermethylation of cytosines have also been observed in the promoter regions of suppressor genes and are considered to contribute to tumor formation.[20](#cas14104-bib-0020){ref-type="ref"}

In the current study, we investigated DNA methylation changes in the liver tissues of F2 C3H male mice that was induced by gestational arsenite exposure of F0 females. In particular, we measured 5mC and 5hmC content of in the genome using liquid chromatography tandem mass spectrometry (LC‐MS/MS) and detected genome‐wide site‐specific DNA methylation using a reduced‐representation bisulfite sequencing (RRBS) method.[21](#cas14104-bib-0021){ref-type="ref"} The results of this study propose novel DNA methylation‐dependent pathways that increase hepatic tumors in the F2 males following gestational arsenite exposure.

2. MATERIALS AND METHODS {#cas14104-sec-0002}
========================

2.1. Animal and arsenite treatment {#cas14104-sec-0003}
----------------------------------

Animal experiments were performed as previously described.[12](#cas14104-bib-0012){ref-type="ref"} Briefly, pregnant C3H/HeN mice (F0) were purchased from CLEA Japan (Tokyo, Japan) and given free access to a standard diet (CA‐1; CLEA Japan) and tap water with or without 85 ppm sodium arsenite (Sigma, St.Louis, MI, USA) from d 8 to d 18 of gestation.[12](#cas14104-bib-0012){ref-type="ref"} Throughout the experiments, arsenite was only given to F0 pregnant mice and not to F1 or F2 mice. F1 male and female mice were mated at 10 wk of age. The F2 males were reared until around 74 wk of age and used for the assessment. Hepatic tumors were visually separated from the livers. All animal procedures were approved by the Animal Care and Use Committee of the National Institute for Environmental Studies (NIES), Japan. All animals were treated humanely in accordance with the NIES guideline for animal experiments.

2.2. Measurement of 5mC and 5hmC amounts {#cas14104-sec-0004}
----------------------------------------

Five genomic DNA (gDNA) samples from 5 mice born to different dams were used per group. gDNA (1 μg) was hydrolyzed as described previously.[22](#cas14104-bib-0022){ref-type="ref"} Standard materials 5‐hydroxymethyl‐2′‐deoxycytidine and 5‐hydroxymethyl‐2′‐deoxycytidine‐d~3~ were purchased from Toronto Research Chemicals Inc (North York, Canada). Internal standards, ie 100 ng ^13^C~9~,^15^N~3~‐2′‐deoxycytidine, 10 ng ^13^C~10~,^15^N~2~‐5‐methyl‐2′‐deoxycytidine,[23](#cas14104-bib-0023){ref-type="ref"} and 1 ng 5‐hydroxymethyl‐2′‐deoxycytidine‐d~3~ were added to 5 μL of the hydrolyzed sample, and the mixture was diluted with H~2~O. LC‐MS/MS analyses were performed using an LC‐MS‐8040 mass spectrometer and an electrospray ionization (ESI) probe (Shimadzu, Kyoto, Japan) in multiple reaction monitoring mode. Deoxycytidine, 5‐methyldeoxycytidine and 5‐hydroxymethyl‐2′‐deoxycytidine were separated using a reversed‐phase column (Atlantis T3; Waters, Milford, MA, USA) in gradient elution mode. Eluent A was a 10 mmol/L aqueous ammonium acetate solution, and eluent B was methanol. The following gradient eluting system was used at a flow rate of .2 mL/min: 2% B for 5 min, 2%‐8% B over .1 min, hold 3.9 min, 8%‐30% B over 4 min, and hold 2.5 min at a flow rate of .2 mL/min.

2.3. RRBS analysis and identification of differentially methylated cytosines (DMCs) and differentially methylated regions (DMRs) {#cas14104-sec-0005}
--------------------------------------------------------------------------------------------------------------------------------

Reduced‐representation bisulfite sequencing analysis was performed as previously described.[24](#cas14104-bib-0024){ref-type="ref"} Briefly, gDNA was prepared from 3 mice from different litters per group by phenol‐chloroform extraction and 100 ng of gDNA was used per sample for RRBS library preparation. The libraries were sequenced on an Illumina HiSeq2500. The sequencing reads were mapped on the mouse reference genome (mm10) with the use of the Bismark program[25](#cas14104-bib-0025){ref-type="ref"} and adapter trimming and quality control was performed using Trim Galore software (<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>). The methylation status of each CpG was calculated using the read.Bismark function of methylKit package (v. 0.9.4)[26](#cas14104-bib-0026){ref-type="ref"} in R. DMCs and DMRs were selected using the methylKit package and eDMR package[27](#cas14104-bib-0027){ref-type="ref"} in R, respectively. DMC was defined as the CpG site with \>20% methylation difference between the 2 groups, \<.01 *q*‐value by the logistic regression method, and \>10 reads in coverage in both groups. DMR was defined as the region that contained \>3 CpGs and one DMC and whose methylation level was different over 20% with a statistically significant difference between the 2 groups. The distance of DMRs from the transcription start sites (TSSs) of the closest RefSeq genes were extracted using bedtools 2.25.0 (bedtools.readthedocs.io). Sequence data are publicly available at Gene Expression Omnibus (GEO), accession number [GSE111420](GSE111420) for CCN and CCTt, and [GSE123749](GSE123749) for the other 4 groups (CCTn, AAN, AATn, and AATt).

2.4. RNA isolation, microarray analysis, and quantitative reverse‐transcription polymerase chain reaction {#cas14104-sec-0006}
---------------------------------------------------------------------------------------------------------

Total RNA was extracted from tissues or cultured cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Qualities of RNA samples were checked using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Total RNA was hybridized to the SurePrint G3 Mouse GE 8x60K Microarray (Agilent Technologies) according to the manufacturer\'s protocol. Signal intensities were normalized to the 75th percentile of all measurement using Agilent Gene‐Spring GX software. The expression data flagged "glsSaturated = 0," "glsFeatPopnOL = 0," "gls Feat NonUnifOL = 0" and "glsWellaboveBG = 1" were utilized for analysis of liver tissues. The genes with a ≥2‐ fold increase or decrease in mean expression values (n = 3) were judged to be changed. In the experiment for Hepa1c1c7 cells with or without overexpression of *Cd74* or *Tmem54*, genes with raw expression values of \>50, and genes with an at least 2‐fold increase or decrease were utilized for further analysis. Array data are publicly available at GEO, accession number [GSE104627](GSE104627) for CCN and CCTt groups and [GSE123737](GSE123737) for CCTn, AAN, AATn, and AATt. Array data for Hepa1c1c7 cells are available at GEO, accession number [GSE123718](GSE123718).

cDNA synthesis and RT‐qPCR analysis were performed as described previously.[28](#cas14104-bib-0028){ref-type="ref"} The primer sequences and annealing temperatures are shown in Table [S1](#cas14104-sup-0005){ref-type="supplementary-material"}.

2.5. Cell culture and treatment {#cas14104-sec-0007}
-------------------------------

Murine hepatic stellate cell line GRX cells (0094) were purchased from the Rio de Janeiro Cell Bank (Rio de Janeiro, Brazil). Murine hepatoma cell line Hepa1c1c7 cells, Hepa1‐6 cells, and GRX cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) (Sigma, D5796) with 1% penicillin/streptomycin and10% fetal bovine serum (FBS). 5‐Aza‐2‐deoxycytidine (5‐aza‐dC) was obtained from Santa Cruz Biotechnology. Cells were seeded into 6‐well culture plates at a density of 3‐5 × 10^5^ cells per well. After 24 h, cells were treated in culture medium with 1‐100 μmol/L 5‐aza‐dC for 72 h and subjected to bisulfite sequencing analysis. Mouse ORF clones *Tmem54* (MC203978), *Cd74* (MC200462), and pCMV6‐Kan/Neo vectors were purchased from Origene Inc (Rockville, MD, USA). Cells were transfected with these vectors using Amaxa nucleofector II (Lonza, Basel, Switzerland) according to the manufacturer\'s instructions. Briefly, 1 × 10^6^ of Hepa1c1c7 cells were transfected with 2 μg of each vector using the Nucleofector Kit V (program X‐005). After 24 h, cells were collected and subjected to real‐time PCR and microarray analysis.

2.6. Bisulfite sequencing analysis and pyrosequencing {#cas14104-sec-0008}
-----------------------------------------------------

Five gDNA samples were isolated from 5 mice obtained from different litters per group. Bisulfite sequencing analysis was performed as previously described.[29](#cas14104-bib-0029){ref-type="ref"} The bisulfite‐treated gDNA were amplified with the primers shown in Table [S1](#cas14104-sup-0005){ref-type="supplementary-material"}. PCR products were purified and cloned into the pGEM‐T Easy Vector (Promega, Madison, WI, USA). Obtained clones were cycle sequenced using M13RV primers and the BigDye Terminator version 3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA), and analyzed using an Applied Biosystems 3730 DNA analyzer. Pyrosequencing was performed as described previously.[12](#cas14104-bib-0012){ref-type="ref"} Briefly, bisulfite‐modified gDNAs were amplified by PCR. Primers are shown in Table [S1](#cas14104-sup-0005){ref-type="supplementary-material"}. We performed sequencing of the products using the PryoMark Q96 ID System (Qiagen) according to the manufacturer\'s protocol.

2.7. Gene expression analysis of human hepatocellular carcinoma {#cas14104-sec-0009}
---------------------------------------------------------------

Human hepatocellular carcinoma (HCC) data were acquired from the TCGA database (<http://cancergenome.nih.gov/>) as previously described.[24](#cas14104-bib-0024){ref-type="ref"} Fifty paired RNA‐seq datasets of normal livers and HCC tissues were downloaded and used for gene expression analysis.

2.8. Survival analysis {#cas14104-sec-0010}
----------------------

We analyzed the clinical data of liver hepatocellular carcinoma (LIHC) using Oncolnc (<http://www.oncolnc.org/>), which can link TCGA survival data to mRNA expression levels. The survival data were separated to 2 groups, a high expression group (top 33%) and a low expression group (bottom 33%), and were assessed for the correlation between survival and gene expressions.

2.9. Statistical analysis {#cas14104-sec-0011}
-------------------------

Statistical significance was determined using Student\'s *t* test or the Tukey‐Kramer test. *P*‐values \< .05 were considered significant. For survival analysis, the log‐rank test was performed and *P*‐values \< .05 were considered significant.

3. RESULTS {#cas14104-sec-0012}
==========

3.1. Contents for genomic 5mC and 5hmC decreased in tumor tissues but were not changed between F2 males of the control group and the arsenite group {#cas14104-sec-0013}
---------------------------------------------------------------------------------------------------------------------------------------------------

Levels of genomic 5mC and 5hmC are substantially reduced in cancer tissues. These changes are implicated in compromised genomic integrity and tumorigenesis.[18](#cas14104-bib-0018){ref-type="ref"}, [19](#cas14104-bib-0019){ref-type="ref"}, [20](#cas14104-bib-0020){ref-type="ref"} Therefore, we investigated whether reductions in 5mC and 5hmC levels were involved in tumor increase in F2 males following gestational arsenic exposure of F0 females. To determine the content of 5mC and 5hmC in the liver genome, we made accurate measurements of these in hepatic tissues of the F2 males by performing LC‐MS/MS with stable isotope‐labeled surrogates as the internal standards. We defined F2 males obtained by crossing control F1 males and females as control (CC), and those obtained by crossing gestationally arsenite‐exposed F1 males and females as arsenite (AA). The normal liver tissues (N) and the nontumor (Tn) and tumor tissues (Tt) of tumor‐bearing livers were designated CCN, CCTn, and CCTt for the control group and AAN, AATn, and AATt for the arsenite group, respectively. We observed that the content of genomic 5mC was significantly decreased in tumor tissues compared with normal tissues both in the control and arsenite groups (Table [1](#cas14104-tbl-0001){ref-type="table"}). As with the reduction in 5mC, content of genomic 5hmC was also significantly decreased in tumor tissues compared with normal tissues. However, there were not any significant changes in the content of genomic 5mC and 5hmC between the control and arsenite groups. These results indicated that reductions in total levels of 5mC and 5hmC were not involved in tumor increase in the F2 males from the arsenite group.

###### 

The contents of genomic 5mC and 5hmC in the liver tissues of F2 males

  F2            Control                Arsenite                                                                                                                                                         
  ------------- ---------------------- ----------------------------------------------------------------------------------------------- ------------ --------------------------------------------------- ------------------------------------------------------------------------------------------------
  5mC           \% in total cytosine   \% in total cytosine                                                                                                                                             
  5.66 ± .05    5.63 ± .04             5.30 ± .19[a](#cas14104-note-0001){ref-type="fn"} ^,^ [b](#cas14104-note-0001){ref-type="fn"}   5.64 ± .04   5.77 ± .07[a](#cas14104-note-0001){ref-type="fn"}   5.28 ± .13[a](#cas14104-note-0001){ref-type="fn"} ^,^ [b](#cas14104-note-0001){ref-type="fn"}
  5hmC          \% of (5mC + 5hmC)     \% of (5mC + 5hmC)                                                                                                                                               
  10.27 ± .34   10.40 ± .38            3.50 ± .93[a](#cas14104-note-0001){ref-type="fn"} ^,^ [b](#cas14104-note-0001){ref-type="fn"}   9.92 ± .31   10.21 ± .60                                         3.46 ± 1.43[a](#cas14104-note-0001){ref-type="fn"} ^,^ [b](#cas14104-note-0001){ref-type="fn"}

Significantly changed compared with a control tissues b nontumor tissues.

John Wiley & Sons, Ltd

3.2. Genome‐wide DNA methylation profiles in the normal and tumor liver tissues of F2 males analyzed using the RRBS method {#cas14104-sec-0014}
--------------------------------------------------------------------------------------------------------------------------

Next, to detect site‐specific changes in DNA methylation, we performed RRBS analysis. We obtained 1 975 828 CpG sites with at least 10× coverage in all samples. The average DNA methylation levels of the 3 types of liver tissues in the control group (CCN, CCTn and CCTt) and those in the arsenite group (AAN, AATn and AATt) are shown in Figure [1](#cas14104-fig-0001){ref-type="fig"}A. The average methylation levels ranged from 30.5 (AATt) to 31.5% (CCN) (Figure [S1](#cas14104-sup-0001){ref-type="supplementary-material"}A). Upstream regions far from TSSs were highly DNA methylated, and the methylation levels gradually decreased toward TSSs, where they troughed at approximately 3%. The regions downstream of TSSs were again highly methylated except around the immediate vicinity of transcription end sites (TESs), where methylation levels dropped to approximately 20% (Figure [1](#cas14104-fig-0001){ref-type="fig"}A). The numbers of CpG sites were highly enriched in TSS regions and modestly in TES regions (Figure [S1](#cas14104-sup-0001){ref-type="supplementary-material"}B).

![Average DNA methylation levels in F2 livers determined by reduced‐representation bisulfite sequencing analysis. A, DNA methylation levels in relation to distance from the transcriptional start site (TSS). We plotted DNA methylation levels in each 100 bp at intergenic regions and plotted in each 1% at intragenic region. B, Region‐specific changes of DNA methylation levels](CAS-110-2629-g001){#cas14104-fig-0001}

Comparison of methylation levels in the 6 groups showed that the intergenic regions far from the TSSs and TESs (Figure [1](#cas14104-fig-0001){ref-type="fig"}B\[1\]\[2\]\[6\]\[7\]) were significantly DNA hypomethylated in tumor tissues compared with normal and nontumor tissues. Gene body regions (Figure [1](#cas14104-fig-0001){ref-type="fig"}B\[4\]) were also slightly hypomethylated in tumor tissues, although not significantly. In contrast, the regions around TSSs were significantly hypermethylated in CCTt (Figure [1](#cas14104-fig-0001){ref-type="fig"}B\[3\]). The regions around TSSs were also slightly hypermethylated in AATt compared with normal tissues and nontumor tissues, although not significantly. DNA methylation levels around TES regions (Figure [1](#cas14104-fig-0001){ref-type="fig"}B\[5\]) were not changed among the groups. We did not detect any significant changes in the average DNA methylation levels between the control groups and arsenite groups.

3.3. Detection of region‐specific DNA methylation changes in the F2 livers associated with gestational arsenite exposure of F0 mice {#cas14104-sec-0015}
-----------------------------------------------------------------------------------------------------------------------------------

To determine specific DNA methylation changes between groups, we detected DMCs and DMRs using methylKit and eDMR packages in R. We have reported a comparison between CCN and CCTt elsewhere.[24](#cas14104-bib-0024){ref-type="ref"} To confirm the success of the analysis, we compared the differences between the AAN group and AATt group. As a result, 24 495 hyper‐DMCs and 60 646 hypo‐DMCs were detected in AATt compared with AAN (Figure [S2](#cas14104-sup-0002){ref-type="supplementary-material"}A\[1\]). The number of hypo‐DMCs was higher than that of hyper‐DMCs in almost all chromosomes (Figure [S2](#cas14104-sup-0002){ref-type="supplementary-material"}A\[2\],\[3\]). The distribution of DMCs in genomic regions showed that approximately 40% of hyper‐DMCs were detected in the promoter and exon regions, whereas over 80% of hypo‐DMCs were detected outside the promoter and exon regions (Figure [S2](#cas14104-sup-0002){ref-type="supplementary-material"}A\[4\]). These results were successfully consistent with the tumor features previously reported.[30](#cas14104-bib-0030){ref-type="ref"}

Next, to detect DMCs and DMRs caused by gestational arsenite exposure, we compared RRBS data between the control and arsenite groups. The numbers of DMCs and DMRs were determined by comparisons between the control and arsenite groups in normal tissues, nontumor tissues, and tumor tissues, respectively. We detected 107 DMRs between CCN and AAN, 57 DMRs between CCTn and AATn, and 1547 DMRs between CCTt and AATt, respectively. Among these, we extracted DMRs at ±2000 bp of the TSS (promoter DMR) to seek DMRs that are closely associated with gene expression (Table [S2](#cas14104-sup-0006){ref-type="supplementary-material"}). Then we checked these DMRs in relation to gene expression using microarray data. We selected the candidate genes that might have been affected by gestational arsenite exposure as follows: (a) DNA methylation changes of DMRs and gene expression changes were negatively correlated; (b) at least 2‐fold expression changes were detected; and (c) raw microarray signals were not lower than 1000. In CCTt vs AATt, 2 genes, *Tmem54* and *Cd74*, met all the criteria, while no candidate genes were detected by comparison of CCN vs AAN or CCTn vs AATn.

3.4. Validation of gene expression and DNA methylation of *Tmem54* and *Cd74* in the hepatic tumors of F2 males {#cas14104-sec-0016}
---------------------------------------------------------------------------------------------------------------

We focused on *Tmem54* (transmembrane protein 54) and *Cd74* (CD74 antigen). TMEM54 was identified as a component of the ubiquitin ligase complex including a cullin region, which is also conserved in mice orthologs.[31](#cas14104-bib-0031){ref-type="ref"} Figure [2](#cas14104-fig-0002){ref-type="fig"}A shows the DMR region displayed using the Integrative Genomics Viewer (IGV). Figure [2](#cas14104-fig-0002){ref-type="fig"}B shows the methylation levels of promoter DMR of *Tmem54* obtained by RRBS analysis for normal tissues, nontumor tissues, and tumor tissues in the control and arsenite groups. The data showed statistically significant hypomethylation in AATt compared with CCTt. We confirmed DNA methylation levels of cytosines in the DMR for CCTt and AATt by bisulfite sequencing analysis. The analyzed region is shown in Figure [2](#cas14104-fig-0002){ref-type="fig"}A (marked as Bisulfite‐seq.) and the sequencing results of the region in 5 CCTt samples and 5 AATt samples are shown in Figure [2](#cas14104-fig-0002){ref-type="fig"}C,D. Among the 38 CpG sites analyzed, methylation levels of 8 sites were significantly decreased in AATt compared with CCTt (Figure [2](#cas14104-fig-0002){ref-type="fig"}D). The total methylation levels of the region were also significantly reduced in AATt (Figure [2](#cas14104-fig-0002){ref-type="fig"}D). Figure [2](#cas14104-fig-0002){ref-type="fig"}E shows the *Tmem54* expression in the 6 groups. The data show that *Tmem54* expression is specifically upregulated in the tumors and is significantly upregulated in AATt compared with CCTt. These results suggested that expression of Tmem54 is upregulated by some factors in tumor tissues (CCTt and AATt) and reduction of DNA methylation in the DMR by gestational arsenic exposure of F1 males is involved in the upregulation of *Tmem54* in AATt compared with the expression in CCTt.

![Validation of the promoter differentially methylated region (DMR) and the gene expression of *Tmem54* in AATt and CCTt. A, Visualizing reduced‐representation bisulfite sequencing (RRBS) data for DNA methylation levels around the transcriptional start site (TSS) of *Tmem54* by Integrative Genomics Viewer (IGV). B, DNA methylation levels of *Tmem54* DMR obtained by RRBS analysis. C, Bisulfite sequencing analysis of *Tmem54* DMR. ○, Unmethylated cytosine; ●, methylated cytosine. D, DNA methylation levels of *Tmem54* DMR calculated from the data of bisulfite sequencing shown in C. E, Expression of *Tmem54* measured by real‐time polymerase chain reaction (PCR)](CAS-110-2629-g002){#cas14104-fig-0002}

CD74 is also a transmembrane protein and a transcription regulator functioning by interacting with the transcription factors RUNX and NF‐κB.[32](#cas14104-bib-0032){ref-type="ref"} The DMR region of *Cd74* is shown in Figure [3](#cas14104-fig-0003){ref-type="fig"}A. The methylation levels of *Cd74* DMR obtained by RRBS analysis in normal tissues, nontumor tissues, and tumor tissues in the control and arsenite group are shown in Figure [3](#cas14104-fig-0003){ref-type="fig"}B. The *Cd74* DMR in AATt is significantly hypomethylated compared with CCTt, and also compared with CCN, AAN, and CCTn. The methylation level of DMC in *Cd74* DMR was validated for CCTt and AATt using pyrosequencing (Figure [3](#cas14104-fig-0003){ref-type="fig"}C). *Cd74* expression was confirmed to be significantly increased in AATt in comparison with CCTt, CCN, AAN, and CCTn using real‐time PCR (Figure [3](#cas14104-fig-0003){ref-type="fig"}D). These results demonstrated that the DNA methylation levels of DMR and gene expression were inversely correlated in *Cd74,* suggesting the involvement of DNA methylation in gene expression regulation.

![Validation of the differentially methylated cytosine (DMC) and the gene expression of *Cd74* in AATt and CCTt. A, Visualizing reduced‐representation bisulfite sequencing (RRBS) data for DNA methylation levels around TSS region of *Cd74* by Integrative Genomics Viewer (IGV). Arrowhead shows the DMC that was assessed by pyrosequencing. B, DNA methylation levels of *Cd74* DMR obtained by RRBS analysis. C, Pyrosequencing analysis of the DMC of *Cd74*. D, mRNA expression of *Cd74* measured by real‐time polymerase chain reaction (PCR)](CAS-110-2629-g003){#cas14104-fig-0003}

3.5. Expression of *Tmem54* and *Cd74* is upregulated by 5‐aza‐dC treatment in hepatoma cells {#cas14104-sec-0017}
---------------------------------------------------------------------------------------------

To determine whether DNA methylation changes in the DMRs of *Tmem54* and *Cd74* are involved in the expression regulation of these genes, we confirmed the relationship using the DNA methylation inhibitor 5‐aza‐dC in the culture of murine hepatoma cell line Hepa1c1c7 cells and hepatic stellate cell line GRX cells. 5‐Aza‐dC treatment of Hepe1c1c7 cells showed upregulation of *Tmem54* in a dose‐dependent manner (Figure [4](#cas14104-fig-0004){ref-type="fig"}A). DNA methylation of the same 38 CpG sites in the DMR region of *Tmem54*, as shown in Figure [2](#cas14104-fig-0002){ref-type="fig"}A, were confirmed to be reduced by 5‐aza‐dC treatment (Figures [4](#cas14104-fig-0004){ref-type="fig"}B, [S3](#cas14104-sup-0003){ref-type="supplementary-material"}A). Significant upregulation of *Tmem54* (Figure [4](#cas14104-fig-0004){ref-type="fig"}C) and hypomethylation of CpGs in the DMR (Figures [4](#cas14104-fig-0004){ref-type="fig"}D, [S3](#cas14104-sup-0003){ref-type="supplementary-material"}B) was also confirmed by 5‐aza‐dC treatment of GRX cells.

![5‐Aza‐dC treatment inhibits DNA methylation of *Tmem54* DMR and upregulates mRNA expression in Hepa1c1c7 cells and GRX cells. Expression of *Tmem54* was measured in Hepa1c1c7 cells treated with different doses of 5‐aza‐dC (A) or GRX cells treated with 50 μmol/L of 5‐aza‐dC (C) by real‐time PCR. The methylation level of each CpG site in the DMR was validated in Hepa1c1c7 cells (B) and GRX cells (D) by bisulfite sequencing](CAS-110-2629-g004){#cas14104-fig-0004}

Likewise, *Cd74* expression was upregulated (Figure [5](#cas14104-fig-0005){ref-type="fig"}A,C,E) and DMC in the DMR was hypomethylated (Figure [5](#cas14104-fig-0005){ref-type="fig"}B,D,F) by 5‐aza‐dC treatment of Hepa1c1c7 cells, Hepa1‐6 cells, and GRX cells. These data support the notion that DNA methylation changes in *Tmem54* and *Cd74* are involved in gene expression.

![5‐Aza‐dC treatment inhibits DNA methylation of *Cd74* DMR and upregulates mRNA expression in murine hepatic cells. mRNA expression of *Cd74* was measured in Hepa1c1c7 cells treated with different doses of 5‐aza‐dC (A), Hepa1‐6 cells treated with 1 μmol/L of 5‐aza‐dC (C), or GRX cells treated with 50 μmol/L of 5‐aza‐dC (E) by real‐time polymerase chain reaction (PCR). Methylation level of *Cd74* DMC was measured in Hepa1c1c7 cells (B), Hepa1‐6 cells (D) or GRX cells (F) by pyrosequencing](CAS-110-2629-g005){#cas14104-fig-0005}

3.6. Overexpression of *Cd74* suppressed tumor suppressor genes *Atoh8* and *Id3*, and increased *Trib3* in hepatoma cells {#cas14104-sec-0018}
--------------------------------------------------------------------------------------------------------------------------

To explore the involvement of upregulation of *Tmem54* and *Cd74* in hepatic tumor increase, we performed overexpression experiments with Hepa1c1c7 cells. We confirmed that both *Cd74* and *Tmem54* mRNA were strikingly induced by each transfection (Figure [6](#cas14104-fig-0006){ref-type="fig"}A). Then, we performed microarray analysis to identify genes whose expressions were affected by overexpression of *Tmem54* or *Cd74*. We selected candidate genes downstream of *Cd74* or *Tmem54* that might be related to tumor formation as follows: (a) the concordant directions of expression changes were observed in AATt compared with AAN in the microarray data of F2 males; and (b) they are reported as tumor‐related genes in PubMed. We validated mRNA expression of the candidate genes in Hepa1c1c7 cells and in tumor tissues of the F2 males using real‐time PCR and confirmed by real‐time PCR that the expression of *Id3* and *Atoh8* was decreased and that of *Trib3* was increased by overexpression of *Cd74* in Hepa1c1c7 cells (Figure [6](#cas14104-fig-0006){ref-type="fig"}B) and in AATt compared with AAN (Figure [S4](#cas14104-sup-0004){ref-type="supplementary-material"}). We also measured the expression of these genes in CCN and CCTt in the F2 males (Figure [S4](#cas14104-sup-0004){ref-type="supplementary-material"}). The results indicated that the expression of *Id3* and *Atoh8* was decreased and that of *Trib3* was increased in tumor tissues both in the control and arsenite groups to a similar extent. The findings implied that those genes were regulated in a tumor‐specific manner by some factors in the hepatic tumors and *Cd74* was not involved in the regulation, at least around the stage investigated. We discuss the regulatory mechanism of *Cd74* in Discussion section. Conversely, we did not detect any significant mRNA changes by *Tmem54* overexpression (data not shown).

![Overexpression of *Cd74* in Hepa1c1c7 cells induces expression changes in cancer‐related genes. A, Validation of overexpression of *Cd74* or *Tmem54* in Hepa1c1c7 cells transfected with each vector. B, Real‐time polymerase chain reaction (PCR) validation of mRNA expression changes in *Id3*,*Atoh8*, and *Trib3* by *Cd74* overexpression](CAS-110-2629-g006){#cas14104-fig-0006}

3.7. High expression of *TMEM54*,*CD74*, and *TRIB3* and low expression of *ATOH8* were associated with human liver hepatocellular carcinoma {#cas14104-sec-0019}
--------------------------------------------------------------------------------------------------------------------------------------------

To seek information on the association of *Tmem54* with a hepatic tumor increase, we analyzed the expression of *TMEM54* in HCC using the TCGA database. Expression of *TMEM54* was found to be increased in human HCC compared with nontumor tissues (Figure [7](#cas14104-fig-0007){ref-type="fig"}A). In addition, prognosis was poorer in HCC with high *TMEM54* expression than in those with low expression (Figure [7](#cas14104-fig-0007){ref-type="fig"}B). Likewise, expression of *CD74* and *TRIB3* was increased and *ATOH8* was decreased in human HCC, as observed in AATt, in comparison with CCTt in the F2 males (Figure [6](#cas14104-fig-0006){ref-type="fig"}A). High expression of *TRIB3* and low expression of *ATOH8* predicted a poor prognosis (Figure [6](#cas14104-fig-0006){ref-type="fig"}B).

![Expression of *TMEM54*,*CD74* and CD74‐downstream genes in human hepatocellular carcinoma (HCC) and correlation with survival. A, Relative expression of genes in HCC compared with pair‐matched noncancer tissues. B, Kaplan‐Meier survival curves of patients with HCC categorized by gene expression levels](CAS-110-2629-g007){#cas14104-fig-0007}

4. DISCUSSION {#cas14104-sec-0020}
=============

In this study, to identify DNA methylation changes involved in a hepatic tumor increase in F2 males by gestational arsenite exposure, we measured the contents of genomic 5mC and 5hmC by LC‐MS/MS and performed RRBS analysis that could detect genome‐wide DNA methylation levels of each CpG site in the 3 types of liver tissues (normal tissues, and nontumor and tumor tissues of tumor‐bearing livers) in a control group and arsenite group.

The contents of genomic 5mC and 5hmC were reduced in tumor tissues compared with normal tissues both in the control and arsenite groups by LC‐MS/MS analysis (Table [1](#cas14104-tbl-0001){ref-type="table"}). This result is consistent with previous reports that the contents of 5mC and 5hmC were reduced in human HCC.[33](#cas14104-bib-0033){ref-type="ref"}, [34](#cas14104-bib-0034){ref-type="ref"} Conversely, this difference was not detected in the contents of 5mC or 5hmC in normal tissues, nontumor tissues, and tumor tissues between the control group and arsenite group (Table [1](#cas14104-tbl-0001){ref-type="table"}).

Next, we compared the RRBS data between the control group and arsenite group. We could not detect any significant changes in DNA methylation levels in individual regions classified by TSS distance between the control group and arsenite group (Figure [1](#cas14104-fig-0001){ref-type="fig"}B). Conversely, a precise analysis of DMR revealed that the promoter DMR of *Cd74* and *Tmem54* were significantly hypomethylated in AATt compared with CCTt (Figures [2](#cas14104-fig-0002){ref-type="fig"}, [3](#cas14104-fig-0003){ref-type="fig"}). Furthermore, the DNA methylation changes in these DMRs were shown to be related to regulation of gene expression by treatment with 5‐aza‐dC in murine hepatoma cell lines and an hepatic stellate cell line (Figures [4](#cas14104-fig-0004){ref-type="fig"}, [5](#cas14104-fig-0005){ref-type="fig"}). The DMRs of *Tmem54* and *Cd74* represented arsenite‐induced tumor‐specific changes as they were not detected from comparison of CCN vs AAN or CCTn vs AATn. The 2 DMRs were also not detected from comparison of CCN vs CCTt reported in our previous study.[24](#cas14104-bib-0024){ref-type="ref"}

In contrast with the broad DMR of *Tmem54,* we only detected 3 CpG sites with one DMC in the DMR of *Cd74*. Gene expression regulation by single‐site methylation has been reported in previous studies.[35](#cas14104-bib-0035){ref-type="ref"}, [36](#cas14104-bib-0036){ref-type="ref"} A single 5‐methylation of cytosine affects transcription factor binding through changes such as long‐range allosteric effects in DNA[37](#cas14104-bib-0037){ref-type="ref"} and transcription factor binding.[38](#cas14104-bib-0038){ref-type="ref"} These mechanisms might be implicated in regulation of *Cd74* expression by its DMC. On the other hand, there were 29 CpG sites on one strand around the *Cd74* TSS ± 2000 bp in addition to the CpGs we identified. However, as the coverage of these CpGs was \<10 or not read at all in the present RRBS analysis, they were not subjected to analysis. Therefore, we could not exclude the possibility that DNA methylation of other CpG sites in the promoter region in addition to the DMR identified in the present study were involved in the regulation of *Cd74* expression.

Although CD74 is not commonly detected in hepatocytes in normal livers, its expression was reported in the hepatocytes of severe acute autoimmune hepatitis patients and Ikkβ‐deleted mouse hepatocytes.[39](#cas14104-bib-0039){ref-type="ref"}, [40](#cas14104-bib-0040){ref-type="ref"} *CD74* is also reported to be expressed in many types of cancers, however the regulatory mechanisms in individual cancers are largely unknown.[41](#cas14104-bib-0041){ref-type="ref"} A recent study reported that CD74 is among the regulated intramembrane proteolysis (RIP) proteins that stay dormant and are activated in response to a variety of stimuli and act as a transcription regulator.[32](#cas14104-bib-0032){ref-type="ref"} As expected, we newly identified downregulation of *Id3* and *Atoh8* and upregulation of *Trib3* by overexpression of *Cd74* in Hepa1c1c7 cells (Figure [6](#cas14104-fig-0006){ref-type="fig"}). Id3 has been reported to induce caspase3‐ and 9‐dependent apoptosis in human keratinocytes,[42](#cas14104-bib-0042){ref-type="ref"} and TRIB3 has been also reported to have an antiapoptotic role in gastric cancer cells exposed to anticancer drugs.[43](#cas14104-bib-0043){ref-type="ref"} Decreased *Id3* and *Atoh8*, and increased *Trib3* were reported to be involved in tumor progression.[44](#cas14104-bib-0044){ref-type="ref"}, [45](#cas14104-bib-0045){ref-type="ref"}, [46](#cas14104-bib-0046){ref-type="ref"} Moreover, the analysis of human HCC data from TCGA disclosed that the increased expression of *CD74* and *TRIB3* and decreased expression of *ATOH8* were also observed in human HCC, and the expression changes were related to poor prognosis (Figure [7](#cas14104-fig-0007){ref-type="fig"}). Therefore, *CD74* activation and subsequent expression changes in the downstream genes, such as *TRIB3* and *ATOH8*, might contribute to human HCC. Consistently, the present study detected downregulation of *Id3* and *Atoh8* and upregulation of *Trib3* in the hepatic tumors in the control and arsenic groups (Figure [S4](#cas14104-sup-0004){ref-type="supplementary-material"}). However, the expression of these genes was not changed between CCTt and AATt, although *Cd74* was upregulated in AATt compared with CCTt. These findings indicated that *Cd74* was not a major regulator of CCTt and AATt in the hepatic tumors of C3H mice around 74 wk of age, although it might be involved in regulation of downstream genes at some point during tumor development in response to tumorigenic stimuli.

In experiments using human tissues and cell lines, TMEM54 (also known as CAC1) is shown to have a pivotal role in activating cyclin‐dependent kinase 2 and progression of the cell cycle.[31](#cas14104-bib-0031){ref-type="ref"} *TMEM54* is also expressed in some cancers and the cell cycle associated function is implicated in carcinogenesis.[31](#cas14104-bib-0031){ref-type="ref"} Our analysis using the human database from TCGA revealed that the expression of *TMEM54* was increased in HCC compared with paired noncancer tissues. Furthermore, an increase in *TMEM54* expression was related to poor prognosis (Figure [7](#cas14104-fig-0007){ref-type="fig"}). These results supported the idea that TMEM54 was related to HCC, suggesting that Tmem54 might have an important role in tumor increase in the F2 males following earlier arsenite exposure.

We examined DNA methylation patterns around the TSS of *TMEM54* and *CD74* using the TCGA database to assess whether DNA methylation is also involved in expression regulation of these genes in human HCC. We utilized DNA methylation data from 377 HCC tissues and 50 normal hepatic tissues. We found that the methylation data from one CpG site (chr1:33 366 802) in the CpG island of *TMEM54*. Mann‐Whitney *U* test demonstrated that there was a statistically significant decrease in methylation in tumor tissues (*P* \< .0001, data not shown). Likewise, methylation data were available for 7 CpGs at ±300 bp from the *CD74* TSS. Results of the Mann‐Whitney *U* test showed that one site upstream of the TSS was significantly hypermethylated and that 6 sites downstream of the TSS were hypomethylated in tumors compared with normal tissues (data not shown). These inverse relationship between DNA methylation and gene expression may implicate DNA methylation regulation of expression of these genes.

Our previous study showed that the tumor augmenting effects following gestational arsenite exposure of F0 mice from gestational day (GD) 8‐18 were transmitted through F1 males, ie via sperm to F2 mice.[12](#cas14104-bib-0012){ref-type="ref"} This period is pivotal for epigenetic reprogramming of primordial germ cells (PGCs), the origin of future F2 mice, in the fetal F1 mice. Perturbation of reprogramming by environmental factors, such as nutrition and chemicals, can give rise to adverse health effects in subsequent generations.[47](#cas14104-bib-0047){ref-type="ref"} As an example, offspring of male mice fed a low‐protein diet exhibited DNA methylation changes associated with expression changes in lipid metabolism‐related genes in the liver,[48](#cas14104-bib-0048){ref-type="ref"} and compositional changes in the transfer RNA fragments in the sire\'s sperm were implicated.[49](#cas14104-bib-0049){ref-type="ref"} Further studies on epigenetic changes in F1 sperm will be needed to identify the mechanism that causes DNA methylation changes associated with F2 mice tumor increase observed in the present study.

Overall, our study proposes novel mechanisms of multigenerational effects of arsenite exposure in that expression of *Cd74* and *Tmem54* was regulated by DNA methylation that involved a tumor increase in F2 males following earlier gestational arsenite exposure.
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